Arterra Bioscience (ARBS) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 reached €2,572,169, up 15% year-over-year, driven by higher sales of cosmetic raw materials and research services.

• Net profit for the period was €1,085,225, a significant increase from €517,261 in the same period last year.

• The company maintained strong liquidity, with cash and cash equivalents at €3,442,220 as of June 30, 2025.

Financial highlights

• Total assets increased to €14,010,275 from €13,401,826 at year-end 2024.

• Equity rose to €11,661,212, reflecting profit retention and allocation to reserves.

• Operating cash flow was €1,529,431, up from €692,472 in the prior year.

• Dividends of €846,780 were distributed from retained earnings.

Outlook and guidance

• The increase in first-half sales and a robust order book for the second half support optimism for achieving 2025 growth targets.